中性粒细胞与淋巴细胞比值及终末期肝病模型（MELD）评分对乙肝相关慢加急性肝衰竭患者短期生存的预测价值
Predictive value of neutrophil-to-lymphocyte ratio and MELD score for short-term survival of patients with HBV-DeCi.
作者信息
Han Zhong, Qi Liangshuai, Chen Sirui, Zhang Jinfei, Guo Xueliang, Liang Chunying, Zheng Weiwei
机构信息
Department of Laboratory Medicine, Shengzhou People's Hospital, Shengzhou Branch of the First Affiliated Hospital of Zhejiang University School of Medicine, the Shengzhou Hospital of Shaoxing University, Shengzhou, Zhejiang, China.
School of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, China.
出版信息
Biomark Med. 2025 Jan;19(2):43-49. doi: 10.1080/17520363.2024.2448112. Epub 2025 Jan 9.
OBJECTIVE
The prognostic value of neutrophil-to-lymphocyte ratio (NLR) combined with Model for End-Stage Liver Disease (MELD) score was evaluated for hepatitis B virus-associated decompensated cirrhosis (HBV-DeCi).
METHODS
The 30-day mortality of 166 hBV-DeCi patients was examined. Receiver operating characteristic curve analysis and multivariate regression analysis were used to assess the performance of NLR for prediction of poor outcomes.
RESULTS
The 30-day mortality rate was 10.2% (17/166). NLR was significantly lower in survivors than in non-survivors, and could be used for prognosis prediction in HBV-DeCi patients. Area under the curve was higher for NLR combined with MELD score than for each factor alone. (MELD score, AUC:0.864、NLR, AUC:0.781, Combined, AUC:0.920) The Odds ratio of MELD score is lower than NLR.(MELD score:1.447&NLR:1.745).
CONCLUSIONS
The findings demonstrate that NLR combined with MELD score has a high prognostic value for HBV-DeCi patients.
目的
评估中性粒细胞与淋巴细胞比值（NLR）联合终末期肝病模型（MELD）评分对乙型肝炎病毒相关性失代偿期肝硬化（HBV-DeCi）的预后价值。
方法
对166例HBV-DeCi患者的30天死亡率进行检测。采用受试者工作特征曲线分析和多因素回归分析来评估NLR预测不良结局的性能。
结果
30天死亡率为10.2%（17/166）。幸存者的NLR显著低于非幸存者，且可用于HBV-DeCi患者的预后预测。NLR联合MELD评分的曲线下面积高于各单一因素。（MELD评分，AUC：0.864；NLR，AUC：0.781；联合，AUC：0.920）MELD评分的优势比低于NLR。（MELD评分：1.447，NLR：1.745）
结论
研究结果表明，NLR联合MELD评分对HBV-DeCi患者具有较高的预后价值。
Zotero 插件